Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
10.71
-0.04 (-0.37%)
At close: Oct 30, 2026, 4:00 PM EDT
10.74
+0.03 (0.26%)
After-hours: Oct 30, 2026, 7:56 PM EDT
Xeris Biopharma Holdings Revenue
Xeris Biopharma Holdings had revenue of $92.10M in the quarter ending June 30, 2026, with 28.74% growth. This brings the company's total for the last twelve months to $335.41M, up 36.33% year-over-year. In the year 2025, Xeris Biopharma Holdings had annual revenue of $291.85M with 43.72% growth. That makes Xeris Biopharma Holdings the 13,738th largest company in the world by revenue and 2,540th in the United States.
Revenue (ttm)
$335.41M
Revenue Growth
+36.33%
P/S Ratio
5.82
Revenue / Employee
$771,067
Employees
435
Market Cap
1.95B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 291.85M | 88.78M | 43.72% |
| Dec 31, 2024 | 203.07M | 39.16M | 23.89% |
| Dec 31, 2023 | 163.91M | 53.67M | 48.68% |
| Dec 31, 2022 | 110.25M | 60.66M | 122.32% |
| Dec 31, 2021 | 49.59M | 29.16M | 142.67% |
| Dec 31, 2020 | 20.44M | 17.71M | 650.73% |
| Dec 31, 2019 | 2.72M | 299.00K | 12.34% |
| Dec 31, 2018 | 2.42M | 867.00K | 55.72% |
| Dec 31, 2017 | 1.56M | 481.00K | 44.74% |
| Dec 31, 2016 | 1.08M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Perrigo Company | 4.14B |
| Phibro Animal Health | 1.52B |
| Trulieve Cannabis | 1.14B |
| Prestige Consumer Healthcare | 1.10B |
| ANI Pharmaceuticals | 978.38M |
| BioCryst Pharmaceuticals | 940.61M |
| Supernus Pharmaceuticals | 830.44M |
| Pacira BioSciences | 746.16M |
XERS News
- 8 days ago - Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - Business Wire
- 15 days ago - Xeris announces presentations on portfolio, pipeline at scientific meetings - TheFly
- 15 days ago - Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings - Business Wire
- 24 days ago - Xeris Biopharma price target raised to $14 from $12 at Barclays - TheFly
- 4 weeks ago - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Reuters
- 4 weeks ago - Lundbeck exploring acquisition of Xeris, Bloomberg reports - TheFly
- 4 weeks ago - Xeris Biopharma tells Bloomberg ‘not for sale’ - TheFly